OncoMatch/Clinical Trials/NCT07278479
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Is NCT07278479 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies [212Pb]Pb-MP0712 for large cell neuroendocrine carcinoma.
Treatment: [212Pb]Pb-MP0712 — The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Neuroendocrine Tumor
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Biomarker criteria
Required: DLL3 expression by IHC
other epNECs with previously confirmed DLL3 expression by IHC
Required: DLL3 positivity by [203Pb]Pb-DOTAM-MAM279 SPECT/CT
DLL3-positivity by [203Pb]Pb-DOTAM-MAM279 SPECT/CT
Disease stage
Required: Stage IV, III
advanced extensive or limited SCLC or LC NECs of the lung; at least one measurable disease per RECIST v1.1
Prior therapy
Must have received: platinum-based chemotherapy — systemic
SCLC (extensive stage, or limited stage) patients with progression or recurrence following at least two prior line of systemic platinum based therapy and immunotherapy
Must have received: immunotherapy — systemic
SCLC (extensive stage, or limited stage) patients with progression or recurrence following at least two prior line of systemic platinum based therapy and immunotherapy
Must have received: systemic therapy — systemic
LC NEC of the lung patients with progression or recurrence following at least one prior line of systemic therapy
Must have received: systemic therapy — systemic
epNECs with progression or recurrence following at least one prior line of systemic therapy
Lab requirements
Blood counts
hemoglobin ≥9 g/dl; absolute neutrophil count (anc) ≥1.5 × 10^9/l; platelets ≥100 × 10^9/l; white blood cells (wbc) ≥2.5 x 10^9/l
Kidney function
calculated glomerular filtration rate (gfr) >60ml/min (using cockroft-gault formula)
Liver function
adequate hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Nebraska Cancer Specialists · Omaha, Nebraska
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07278479 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received platinum-based chemotherapy and immunotherapy.
Does this trial require DLL3?
Yes, DLL3 expression by IHC is a required biomarker for enrollment.
Does this trial require DLL3?
Yes, DLL3 positivity by [203Pb]Pb-DOTAM-MAM279 SPECT/CT is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV or III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify